

Active substances set

Search phrase: Chronic lymphoid leukemia

Below you will find a list of active substances registered by the European Medical Agency (EMA) in the last 15 years, recommended by the European Society of Clinical Oncology (ESMO) and their reimbursement status in the country.

Chronic lymphoid leukemia

Idelalisib	Idelalisib is indicated in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL): - who have received at least one prior therapy, or - as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	NO REIMBURSEMENT ESMO
Obinutuzumab	Obinutuzumab in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated CLL and with comorbidities making them unsuitable for full-dose fludarabine based therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO
Acalabrutinib	Acalabrutinib as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Acalabrutinib in combination with venetoclax with or without obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Acalabrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	REIMBURSEMENT WITH RESTRICTIONS ESMO

Ibrutinib	Ibrutinib as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Ibrutinib as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.	FULL REIMBURSEMENT ESMO
Venetoclax	Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL). Venetoclax in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy. Venetoclax monotherapy is indicated for the treatment of CLL: - in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or - in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.	FULL REIMBURSEMENT ESMO
Zanubrutinib	Zanubrutinib as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL).	FULL REIMBURSEMENT ESMO